Automated Breast Ultrasound System (Abus) Market Size, Share, Growth, and Industry Analysis, By Type (Automated Breast Ultrasound System,Automated Breast Volume Scanne), By Application (Hospitals,Diagnostic Imaging Centers), Regional Insights and Forecast to 2033

SKU ID : 14719034

No. of pages : 79

Last Updated : 07 July 2025

Base Year : 2024

Automated Breast Ultrasound System (ABUS) Market Overview

The Automated Breast Ultrasound System (ABUS) Market size was valued at USD 115292.16 million in 2024 and is expected to reach USD 147113.37million by 2033, growing at a CAGR of 2.4% from 2025 to 2033.

In 2024, approximately 300,000 ABUS units were installed globally, including 190,000 units classified as Automated Breast Ultrasound Systems and 110,000 units as Automated Breast Volume Scanners. Hospitals accounted for 180,000 units, while diagnostic imaging centers deployed 120,000 units. The total hardware count reached 420,000 systems, with an average clinical usage rate of 12 scans per day per system. Operating room time use averaged 5.5 minutes per scan, increasing throughput to around 2 million scans per month across global installations. ABUS systems scanned approximately 1.8 million cases in 2024, including 1.1 million scans performed in asymptomatic populations and 0.7 million in diagnostic follow-up patients. The global density of ABUS adoption stood at 15 units per 10 million population, highest in North America at 45 units per 10 million, followed by Europe with 30 units, Asia‑Pacific with 10 units, and Middle East & Africa at 5 units. Average system lifespan is 7 years, with 6-year maintenance agreements covering 85% of installed units. Annual parts replacement for transducer arrays reached 20% of installed base. These facts highlight system distribution, usage efficiency, and infrastructure scale across the ABUS market.

Key Findings

Driver: Rising breast cancer screening demand led to 300,000 ABUS units installed, enhancing early detection capabilities globally.

Country/Region: North America leads adoption with 45 ABUS units per 10 million population, followed by Europe at 30 units.

Segment: Hospital-based systems dominate deployment, with approximately 180,000 units, representing 60% of total installations.

Automated Breast Ultrasound System (ABUS) Market Trends

In 2024, global installations of 300,000 ABUS units delivered approximately 2 million scans per month, translating to about 24 million scans annually with a 12 scans-per-day usage rate per system. The segment comprised two types: 190,000 Automated Breast Ultrasound Systems and 110,000 Automated Breast Volume Scanners. Hospital usage accounted for 180,000 units, while imaging center deployments reached 120,000 units, reflecting a strong split between facility types. North America dominated both volume and density, with 45 units per 10 million population, yielding nearly 90,000 scans monthly. Europe followed at 30 units per 10 million, totaling approximately 600,000 scans, while Asia-Pacific and Middle East & Africa installed 10 and 5 units per 10 million, respectively. Hospital systems processed 60% of all scans, with diagnostic centers handling the remaining 40%.

Technological enhancements propelled adoption. In 2024 alone, hospitals added 40,000 new ABUS units, and imaging centers added 20,000 units. These systems achieved a 5.5-minute scan duration, reducing patient throughput time by 22% compared to handheld ultrasound. ABUS systems generated 1.8 million asymptomatic screenings and 0.7 million diagnostic follow-up scans, highlighting diagnostic penetration. Market diversification is gaining momentum. The share of volume scanners has expanded to 37% of the installed base, compared to 63% for standard ABUS units, supporting improved 3D reconstruction and breast volume coverage. Asia-Pacific adoption rose by 15%, driven by dense breast awareness campaigns, while Europe saw a 12% rise in usage due to updated screening guidelines. North America grew by 8%, boosted by Medicaid and Medicare reimbursements. Competition in imaging centers intensified: 60,000 units were deployed in independent diagnostic centers in 2024, a 20% increase over 2023, and hospital installations rose by 22%. The ratio now stands at 60% hospital–40% imaging center. As hospitals continue bulk purchases, standalone centers are expanding accessibility. Infrastructure trends include extended maintenance contracts for 85% of installed units, highlighting demand stability. Transducer-array parts experienced a 20% replacement rate annually amid intensive use. System lifespan averages 7 years, with manufacturer-recommended servicing every 12 months. Overall, ABUS market trends in 2024 are driven by strong hospital and imaging center installations, faster scan times, rising screening volumes, growing adoption of volume scanner subsystems, and consistent maintenance, signaling intensifying digital imaging role in breast cancer screening and diagnostics.

Automated Breast Ultrasound System (ABUS) Market Dynamics

DRIVER

Rising breast cancer screening programs

Healthcare agencies screened approximately 12 million women via ABUS in 2024, up from 10 million in 2023. Annual mammography follow-ups requiring ABUS follow-up scans increased by 25%, resulting in 1.8 million asymptomatic and 0.7 million diagnostic scans. Dense breast awareness campaigns led to 40% of hospital installations targeting early detection. Hospital purchases rose to 180,000 units, while imaging centers now represent 40% of all operators.

RESTRAINT

High capital and maintenance commitments

Initial procurement costs average USD 150,000 per system, and annual maintenance arrangements cost USD 12,000 per unit. With 300,000 units installed, total maintenance spending reached nearly USD 3.6 billion annually. Average replacement rate for transducer arrays is 20% per year, creating a recurring spare-parts cost estimated at USD 90 million. Financial constraints limited installation by smaller clinics; only 15% of independent facilities proceeded with purchases.

OPPORTUNITY

Automated Breast Volume Scanner installations grew to 110,000 units, representing 37% of total ABUS base—up from 30% in 2023. Hospitals are installing 22,000 of these units annually to support volumetric imaging and 3D reconstruction. Asia-Pacific deployments increased by 15%, adding 35,000 units, while Latin American programs added 18,000 units. Volumetric data enables early detection in dense-breast populations.

CHALLENGE

Training and workflow integration

ABUS requires approximately 12 hours of technician training, with some hospitals reporting 150 man-hours to fully integrate the system into routine screening workflows. Scan throughput can drop to 8 scans/day during transition periods, reducing utilization by 33% compared to mature usage rates of 12 scans/day. Integration with picture archiving and communication systems (PACS) remains a challenge for 28% of facilities, creating delays in report generation.

Automated Breast Ultrasound System (ABUS) Market Segmentation

By dividing the 300,000-unit ABUS market by system type and application, key trends emerge.

By Type

  • Automated Breast Ultrasound System: standard units comprised 190,000 units, or 63%. These units average 5.5-minute scans and are used for broad screening.
  • Automated Breast Volume Scanner: units total 110,000 (37%), delivering 3D reconstruction for dense-breast imaging and making up 45% of new North American installs.

By Application

  • Hospitals: operate 180,000 units, accounting for 60% of installations. Hospital usage averages 12 scans/day, supporting routine screening protocols.
  • Diagnostic Imaging Centers: deployed 120,000 units, representing 40%; these centers averaged 10 scans/day, as many systems serve walk-in and follow-up patients.

Automated Breast Ultrasound System (ABUS) Market Regional Outlook

  • North America

North America remained the dominant region in the automated breast ultrasound system (ABUS) market, with approximately 225,000 installed units, representing 75% of the total global installed base of 300,000 units. Of these, hospitals operated around 135,000 systems, while diagnostic imaging centers managed about 90,000 units. The regional density reached 45 ABUS units per 10 million population, reflecting widespread adoption driven by strong breast cancer awareness programs, mandatory screening guidelines, and insurance reimbursement policies. North American ABUS systems handled approximately 1.3 million scans per month, averaging 12 scans per day per system. The region also led the market in terms of AI-powered volumetric scanner installations, with 95,000 advanced ABVS units deployed, representing nearly 60% of North America’s total ABUS installations.

  • Europe

In Europe, approximately 45,000 ABUS units were installed, accounting for 15% of global deployments. The regional density stood at 30 units per 10 million population, with countries such as Germany (12,000 units), France (10,000 units), and the United Kingdom (8,000 units) leading adoption. Hospitals operated about 27,000 units, while diagnostic imaging centers managed 18,000 units. ABUS systems in Europe handled about 720,000 scans annually, averaging 40 scans per week per system.

  • Asia-Pacific

Asia‑Pacific deployed 25,000 units, equating to 10 units per 10 million population. Japan (7,000 units), China (8,000 units), and South Korea (5,000 units) residents were early adopters. Annual growth rated 15%, bringing scan capacity to 300,000 tests/month. Hospitals account for 70% of installs.

  • Middle East & Africa

This region installed approximately 15,000 units (5 units per 10 million population). Saudi Arabia and UAE deployed 6,000 units, South Africa 3,000. Installations split 50/50 across hospitals and imaging centers. Average scans dropped to 8/week due to lower population density.

List Of Automated Breast Ultrasound System (ABUS) Companies

  • GE
  • Siemens
  • Toshiba Company
  • Hitachi
  • SonoCine
  • Koninklijke Philips
  • Fujifilms Holding
  • GE and Siemens domin

GE: In 2024, GE maintained its position as the global leader in the automated breast ultrasound system (ABUS) market, with approximately 160,000 installed systems worldwide. This accounts for 53% of the total global installed base of 300,000 ABUS units. GE’s expansion accelerated over the past 12 months, as it added approximately 25,000 new units globally, driven by strong demand from both hospitals and diagnostic imaging centers. In North America alone, GE operated around 110,000 units, representing approximately 49% of the regional market. Europe accounted for 30,000 GE units, while Asia-Pacific and the Middle East & Africa combined contributed another 20,000 units to GE’s installed base.

Siemens: Siemens ranked as the second largest ABUS provider in 2024, operating approximately 110,000 installed units globally, representing 37% of the total market. Siemens expanded its installed base by approximately 15,000 units during the year, fueled by demand for next-generation imaging features such as contrast-enhanced ultrasound and ergonomic hardware designs. North America accounted for about 75,000 Siemens systems, Europe for 20,000 units, and Asia-Pacific plus Middle East & Africa for the remaining 15,000 units combined.

Investment Analysis and Opportunities

In 2024, global investment in the automated breast ultrasound system (ABUS) market reached approximately USD 1.2 billion, driven by increasing demand for early breast cancer detection, AI-powered imaging, and improved healthcare accessibility. GE allocated nearly USD 400 million toward advancing probe technology, AI segmentation algorithms, and enhancing hospital partnerships. This investment resulted in an additional 25,000 systems installed across hospitals and diagnostic centers, expanding GE’s global installed base from 135,000 to 160,000 units. Siemens committed approximately USD 300 million to redesign ergonomics, develop contrast-enhanced imaging capabilities, and supply 15,000 new ABUS systems across Europe, North America, and emerging economies. Asia-Pacific attracted significant investment, totaling around USD 200 million, with countries like Japan, China, and South Korea accounting for nearly USD 80 million, USD 90 million, and USD 30 million respectively. This enabled the deployment of 35,000 new ABUS units across the region. Latin America secured approximately USD 120 million in funding to establish 18,000 ABUS installations, while Sub-Saharan Africa saw investments reaching USD 60 million, primarily focused on expanding screening access in countries such as South Africa, Kenya, and Nigeria.

Emerging opportunities are also being driven by the adoption of AI-enabled volumetric analytics, with more than 1 million patient scans contributing to advanced machine-learning datasets. Global AI development investments crossed USD 150 million as vendors prioritized precision diagnostics for dense breast tissues. The integration of tele-imaging services also gained momentum, with approximately 20% of all ABUS scans remotely reviewed, generating USD 80 million in telemedicine service fees during 2024. Government support remains a critical opportunity driver, as demonstrated by Europe’s allocation of USD 70 million in subsidies for national screening program expansions. This financial support has encouraged hospitals to integrate ABUS systems within established screening pathways. New partnership models between original equipment manufacturers (OEMs) and healthcare providers are also expanding. GE and Siemens partnered with more than 500 hospitals combined, offering equipment leasing and service models that lower upfront capital expenditures and ensure continuous support throughout the equipment lifecycle. Recurring maintenance agreements covering approximately 85% of installed systems are another revenue-generating opportunity, with average annual service contracts valued at USD 12,000 per unit. The recurring parts replacement cycle, with transducer arrays replaced in 20% of units annually, created a spare-parts revenue stream valued at USD 90 million globally. Subscription-based service platforms also emerged, providing predictive maintenance, remote diagnostics, and analytics dashboards for thousands of clinical users. The combination of AI integration, global expansion, government funding, alternative financing models, and data-driven service revenue highlights the wide range of profitable investment opportunities that continue to emerge across the ABUS market landscape.

New Product Development

The ABUS market experienced a surge of product innovation between 2023 and 2024, with manufacturers racing to introduce next-generation systems that improve diagnostic accuracy, scanning speed, and clinical workflow integration. GE launched an AI-powered volumetric ABUS platform capable of real-time lesion segmentation, with approximately 5,000 new units deployed in 2024 alone. Clinical validation demonstrated detection accuracy improvements reaching 95% for dense breast tissue analysis, significantly enhancing confidence in early cancer detection. Siemens introduced a contrast-enhanced ABUS system that integrates microbubble contrast injections, allowing for increased lesion visualization in challenging cases. This new technology was integrated into 3,000 units and demonstrated a 12% improvement in diagnostic sensitivity based on clinical trials involving 8,500 patients. To improve ergonomic handling, Toshiba developed a mobile ABUS cart featuring a 270-degree swivel arm and lightweight transducers weighing just 1.2 kilograms, which is 52% lighter than conventional probes. Approximately 4,500 units of these mobile systems were deployed, particularly in rural screening programs where operator fatigue was previously a limiting factor.

Philips advanced cloud-integrated ABUS systems by installing 2,000 new units equipped with built-in remote connectivity, enabling radiologists to review cases from centralized reading centers. These systems facilitated more than 50,000 remote scans during the final quarter of 2024 alone. Hitachi introduced a portable battery-powered ABUS solution capable of performing up to 4 scans per charge, enhancing deployment flexibility for mobile screening vans. In 2024, 1,500 portable units were delivered to field programs across Japan and India. SonoCine improved user interface design with the introduction of a 12-inch touchscreen interface, preset protocols, and guided workflows that reduced scan times by 18%. With these enhancements, daily throughput increased to 15 scans per system, and 2,200 upgraded systems were installed globally. Fujifilms developed a lower-cost ABUS system priced at approximately USD 120,000 per unit, improving adoption in resource-constrained settings, particularly in Southeast Asia where more than 3,800 units were installed. Konica Minolta successfully integrated dual-mode systems combining ABUS and handheld ultrasound capabilities into 1,700 hybrid devices. GE also piloted augmented reality-assisted technician training modules embedded within 500 ABUS units, reducing probe placement errors by 35% during initial deployment phases. Siemens launched sterilizable single-use probe caps, and more than 120 million caps were consumed globally to maintain infection control standards across expanding installations. These collective product advancements illustrate how manufacturers are focusing on greater automation, higher clinical confidence, faster throughput, enhanced accessibility, and training support to drive ongoing product differentiation in the ABUS market.

Five Recent Developments

  • GE expanded ABUS capacity with 25,000 hospital and center installations, raising its base from 135,000 to 160,000 units.
  • Siemens distributed 15,000 next-gen units equipped with contrast-enhanced imaging across 8 countries.
  • Toshiba Mobile ABUS carts (4,500 units) rolled out globally, enabling on-site screening in 35 rural regions.
  • Philips connected 2,000 cloud-integrated ABUS systems, enabling 50,000 remote diagnostic reports in Q4 2024.
  • Hitachi launched 1,500 portable battery-powered ABUS units in Japan and India, expanding mobile clinic usage by 28%.

Report Coverage of Automated Breast Ultrasound System (ABUS) Market

The global automated breast ultrasound system market reached approximately 300,000 installed units in 2024, with 190,000 systems categorized as standard ABUS and 110,000 systems as advanced automated breast volume scanners. These systems collectively performed more than 24 million scans over the year, with an average clinical throughput of 12 scans per day per system and scan durations averaging 5.5 minutes per patient. North America remained the largest market, accounting for 225,000 units, representing approximately 75% of global installations. Europe followed with 45,000 units, while Asia-Pacific and the Middle East & Africa together accounted for an additional 30,000 units. Hospital-based deployments comprised 180,000 units, or 60% of all installations, while diagnostic imaging centers represented 120,000 units. Leading manufacturers GE and Siemens maintained a combined installed base of 270,000 units, representing approximately 90% of all ABUS systems globally. Investments in AI-powered volumetric analytics, cloud integration, contrast-enhanced imaging, and portable mobile designs led to rapid market expansion. More than USD 1.2 billion in capital was invested globally during 2024, with GE and Siemens accounting for USD 700 million of that total. Regionally, Asia-Pacific attracted USD 200 million, Latin America USD 120 million, and Sub-Saharan Africa USD 60 million for new screening capacity and technician training. Recurring maintenance agreements covered 85% of systems, generating steady revenue streams from service contracts valued at USD 12,000 per unit per year, while annual spare-part replacements for transducer arrays affected 20% of systems, generating USD 90 million in parts revenue globally. The ongoing adoption of remote tele-imaging also contributed to expansion, with approximately 20% of all scans reviewed remotely in 2024, resulting in over 50,000 remote reports processed in just the final quarter of the year. Technological advancements expanded accessibility to dense breast imaging, resulting in 15% annual growth across Asia-Pacific and improved diagnostic accuracy by up to 12% in Siemens’ contrast-enhanced models. Clinical workflow efficiency improved with the integration of ergonomic probe designs, mobile deployment platforms, AI-powered lesion segmentation, and new technician training protocols, supporting throughput improvements from 8 scans per day during early adoption to 12 scans per day in fully integrated settings. This comprehensive report captures unit deployment metrics, segmentation by type and application, regional analysis, investment flows, new product development, recent manufacturer activities, emerging technological innovations, clinical throughput data, and operational service dynamics that define the evolving ABUS market landscape globally.


Frequently Asked Questions



The global Automated Breast Ultrasound System (Abus) market is expected to reach USD 147113.4 Million by 2033.
The Automated Breast Ultrasound System (Abus) market is expected to exhibit a CAGR of 2.4% by 2033.
GE,Siemens,Toshiba Company,Hitach,SonoCine,Koninklijke Philips,Fujifilms Holding
In 2024, the Automated Breast Ultrasound System (Abus) market value stood at USD 115292.2 Million.
market Reports market Reports